BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsEarnings

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 22, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m.

Open original release

Related news

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-02-25 21:05 EST

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

NTLAIntellia2026-05-11 11:30 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

ABEOAbeona Therapeutics2026-03-03 12:30 EST

Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference

CRSPCRISPR Therapeutics2026-02-12 21:30 EST

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

TSHATaysha Gene Therapies2026-05-06 12:00 EST

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Sarepta Therapeutics

Sarepta Therapeutics is a biotechnology company focused on rare neuromuscular diseases, especially Duchenne muscular dystrophy. The company’s identity is closely linked to gene therapy, exon-skipping science, and the progress of its rare-disease franchise.

Recent company news

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-04-22 12:30 EST

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-03-31 20:05 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
15.89 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States